(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 July 2014 (03.07.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/106123 A8

(51) International Patent Classification:
C07K 14/195 (2006.01) *A61K 39/00* (2006.01)
C12N 15/74 (2006.01)

(21) International Application Number:
PCT/US2013/078119

(22) International Filing Date:
27 December 2013 (27.12.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/746,237 27 December 2012 (27.12.2012) US
61/780,744 13 March 2013 (13.03.2013) US

(71) Applicant: **ADURO BIOTECH, INC.** [US/US]; 626 Bancroft Way, 3C, Berkeley, CA 94710-2224 (US).

(72) Inventors: **LAUER, Peter, M.**; 1003 Solano Avenue, Albany, CA 94706 (US). **HANSON, William, G.**; 101 Camrose Place, Walnut Creek, CA 94596 (US). **SKOBLE, Justin**; 2423 Roosevelt Avenue, Berkeley, CA 94703 (US). **LEONG, Meredith Lai, Ling**; 6615 Saroni Drive, Oakland, CA 94611 (US). **FASSO, Marcella**; 57 Southwind Circle, Richmond, CA 94804 (US). **BROCKSTEDT, Dirk**; 57 Southwind Circle, Richmond, CA 94804 (US). **DUBENSKY, Thomas, W., Jr.**; 15 King Avenue, Piedmont, CA 94611 (US).

(74) Agents: **WHITTAKER, Michael, A.** et al.; Acuity Law Group, P.C., 12707 High Bluff Drive, Suite 200, San Diego, CA 92130 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
16 June 2016

(15) Information about Correction:
see Notice of 16 June 2016

(54) Title: SIGNAL PEPTIDE FUSION PARTNERS FACILITATING LISTERIAL EXPRESSION OF ANTIGENIC SEQUENCES AND METHODS OF PREPARATION AND USE THEREOF




FIG.1

(57) Abstract: The present invention provides nucleic acids, expression systems, and vaccine strains which provide efficient expression and secretion of antigens of interest into the cytosol of host cells, and elicit effective CD4 and CD8 T cell responses by functionally linking Listerial or other bacterial signal peptides/secretion chaperones as N-terminal fusion partners in translational reading frame with selected recombinant encoded protein antigens. These N-terminal fusion partners are deleted (either by actual deletion, by mutation, or by a combination of these approaches) for any PEST sequences native to the sequence, and/or for certain hydrophobic residues.

WO 2014/106123 A8